Jose A. Karam, MD, FACS

Peer-Reviewed Articles

1. Ruiz-Cordero R, Wang Q, Kumar G, Akgul M, Creighton CJ, Rao P, Tamboli P, Zheng L, Zhao J, Murugan P, Shen S, Brimo F, Ezhilarasan R, Sulman E, Wani K, Lazar AJ, Kim T, Chen K, Bhat KPL, Kannan K, Wang J, Karam JA, Sircar K. Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples. Eur Urol Oncol, 2025. e-Pub 2025. PMID: 41193273.
2. Tang C, Sherry AD, Seo A, Hara K, Choi H, Liu S, Sun X, Montoya A, Ludmir EB, Shah AY, Jonasch E, Zurita AJ, Kovitz C, Alhalabi O, Goswami S, Hahn AW, Campbell MT, Hernandez A, Nead KT, Van Loo P, Su S, Battey CJ, LaBella ML, Ratzel S, Acevedo A, Genovese G, Sircar K, Karam JA, Tannir NM, Msaouel P. Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. Lancet Oncol 26(10):1289-1299, 2025. e-Pub 2025. PMID: 40915303.
3. Nieto Y, Ward JF, Hofstetter W, Rice D, Karam JA, Pisters L, Vauthey JN, Shah A, Lin JK, Johns AC, Araujo J, Tu SM, Wang J, Li J, Abudayyeh A, Thall PF, Bassett R, Barnett M, Gulbis A, Shigle TL, Ramdial J, Popat U, Qazilbash M, Jones RB, Andersson BS, Shpall EJ, Sheikh I, Pagliaro L, Campbell MT. HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORS. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40853903.
4. Esagian SM, Msaouel P, Karam JA, Gartrell BA, Makrakis D. Temporal Trends and Socioeconomic Determinants of Cytoreductive Nephrectomy Utilization for Metastatic Renal Cell Carcinoma in the USA. Eur Urol Focus, 2025. e-Pub 2025. PMID: 40841252.
5. Ghasemzadeh A, Abel EJ, Karam JA, Spiess PE, Peyton CC, Manley BJ, Sirard RB, Robertson N, Ellis EE, Cotta BH, Patel KR, Nicaise E, Jani A, Sexton WJ, Patil D, Allen GO, Matin SF, Master VA, Shapiro DD. Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy. J Urol:101097JU0000000000004705, 2025. e-Pub 2025. PMID: 40763351.
6. Dabestani S, Azawi NH, Campi R, Jarvinen P, Nisen H, Capitanio U, Nielsen TK, Simone G, Rochester M, Green E, Fernandez-Pello S, Blick C, Porpiglia F, Ingels A, Bratulic S, Antonelli A, Hakimi AA, Jewett MAS, Ljungberg B, Bhindi B, Marconi L, Laird A, Stewart GD, Nair R, Lund L, Barber N, Master VA, Minervini A, Karam JA, Gatto F, Bex A. Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study. Eur Urol Oncol, 2025. e-Pub 2025. PMID: 40866172.
7. Zacharias NM, Ozambela M, Karki M, He R, Chauhan PK, Pesquera PI, Hernandez Gonzalez AE, Ochoa O, Pieretti A, Chen H, De La Cerda C, Yu Z, Grover A, Hicks-Pena S, Fowlkes NW, Wang L, Maity T, Rao P, Genovese G, Tannir NM, Karam JA, Msaouel P. Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. Mol Cancer Ther, 2025. e-Pub 2025. PMID: 40601845.
8. Abdelsalam ME, Awad A, Bassett RL, Lu T, Irwin D, Shah KY, Odisio BC, Habibollahi P, Karam JA, Matin SF, Ahrar K. Technique and Outcomes of Radiofrequency Ablation of Biopsy-Proven 3–4 cm T1a Renal Cell Carcinoma. Biomedicines 13(6), 2025. e-Pub 2025. PMID: 40564015.
9. Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol 8(2):315-323, 2025. e-Pub 2025. PMID: 39013742.
10. Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun 16(1):1846, 2025. e-Pub 2025. PMID: 39984485.
11. Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Buttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nat Cancer 6(2):372-384, 2025. e-Pub 2025. PMID: 39789182.
12. Cotta, BH, Msaouel, P, Karam, JA. Surgical approaches following durable responses to immunotherapy. Kidney Cancer 9, 2025. e-Pub 2025.
13. Fields BC, Newhook TE, Lillemoe HA, Qiao W, Karam JA, Matin SF, Meyer LA, Tzeng CD. 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol. Adv Cancer Educ Qual Improv 1(1), 2025. e-Pub 2025. PMID: 40583965.
14. Machado RD, De Amaro LB, Prudente A, Faria EF, Rodrigues Junior AA, Venkatesan AM, Karam JA, Muglia VF, Reis LO, Borges Dos Reis R. Impact of Active Surveillance on Nephrometric Scores of Bosniak III and IV Renal Cysts. Int J Gen Med 18:4615-4623, 2025. e-Pub 2025. PMID: 40862066.
15. Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Futreal A, Wang L, Tannir NM, Sharma P. Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma. Res Sq, 2024. e-Pub 2024. PMID: 39606482.
16. Zhou X, LeBleu VS, Fletcher-Sananikone E, Kim J, Dai J, Li B, Wu CC, Sugimoto H, Miyake T, Becker LM, Volpert OV, Lawson E, Espinosa Da Silva C, Patel SI, Kizu A, Ehsanipour EA, Sha D, Karam JA, McAndrews KM, Kalluri R. Vascular heterogeneity of tight junction Claudins guides organotropic metastasis. Nat Cancer 5(9):1371-1389, 2024. e-Pub 2024. PMID: 39289595.
17. Esagian SM, Karam JA, Msaouel P, Makrakis D. Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol Focus 11(1):100-108, 2024. e-Pub 2024. PMID: 39289076.
18. Abdelsalam ME, Lu T, Baiomy A, Awad A, Odisio BC, Habibollahi P, Irwin D, Karam JA, Matin SF, Stafford J, Ahrar K. Magnetic resonance imaging–guided renal biopsy shows high safety and diagnostic yield. Eur Radiol 34(9):5551-5560, 2024. e-Pub 2024. PMID: 38400904.
19. Ntowe, KW, Mcadoo, S, Haas, NB, Karam, JA, Lara, PN, Fashoyin-Aje, I, Saraiya, BP, Maskens, D, Pickering, L, Master, VA, Zhang, T, Kaye, D. Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer. Kidney Cancer 8(1):125-134, 2024. e-Pub 2024.
20. El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen CB, Alva A, Fahey CC, Beckermann KE, Karam JA, Campbell MT, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney HP, De Giorgi U, Parikh O, Winquist E, Master V, Garcia AR, Cutuli HJ, Ferguson TR, Gross-Goupil M, Baca SC, Pal SK, Braun DA, McKay RR, Heng DYC, Choueiri TK. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. Eur Urol 86(6):503-512, 2024. e-Pub 2024. PMID: 39147674.
21. Karam JA, Uzzo R, Bex A, Leung W, Tat C, Nicholas A, Andreev-Drakhlin A, Huseni M, Pal SK, Master VA. Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010. Eur Urol Oncol 7(6):1175-1178, 2024. e-Pub 2024. PMID: 38955577.
22. Karam JA, Bhattacharya R, Ogbomo A, Gautam S, Yu R, Sundaram M, Imai K, Chhabra J, Haas NB. Real-world study on the characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups. Cancer Med 13(11):e7247, 2024. e-Pub 2024. PMID: 38826126.
23. Abdelsalam ME, Mecci N, Awad A, Bassett RL, Odisio BC, Habibollahi P, Lu T, Irwin D, Karam JA, Matin SF, Ahrar K. Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience. Cancers (Basel) 16(10), 2024. e-Pub 2024. PMID: 38791894.
24. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med 390(15):1359-1371, 2024. e-Pub 2024. PMID: 38631003.
25. . YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma. JNCCN 22(2.5), 2024. e-Pub 2024. PMID: 38579843.
26. Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol 7(2):266-274, 2024. e-Pub 2023. PMID: 37442673.
27. Mbilinyi RH, Msaouel P, Rao P, Karam JA, Tannir NM, Tang C. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer 22(3), 2024. e-Pub 2024. PMID: 38556389.
28. Borges Dos Reis R, Shu X, Ye Y, Borregales L, Karam JA, Adibi M, Wu X, Reis LO, Wood CG. Urinary miRNAs Predict Metastasis in Patients With Clinically Localized Clear Cell Renal Cell Carcinoma Treated With Nephrectomy. Clin Genitourin Cancer S1558-7673(23):e156-e162.e4, 2024. e-Pub 2024. PMID: 37945405.
29. Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MA. Incidence and Geographical Distribution of Adrenocortical Carcinoma. Endocr Pract S1530-891X(23):25-30, 2024. e-Pub 2024. PMID: 37858722.
30. Makrakis, D, Msaouel, P, Karam, JA, Esagian, SM. The role of cytoreductive nephrectomy (CN) in the immune checkpoint inhibitor (ICI) era of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
31. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
32. . Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy. Urology 182:168-174, 2023. e-Pub 2023. PMID: 37690543.
33. Abdelsalam ME, Hudspeth TN, Leonards L, Kusin SB, Buckley JR, Bassett Jr R, Awad A, Karam JA, Matin SF, Lu T, Ahrar K. Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy. European Urology Open Science 57:45-50, 2023. e-Pub 2023. PMID: 38020520.
34. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 9(5):734-741, 2023. e-Pub 2023. PMID: 36863962.
35. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med 13(5):e1267, 2023. e-Pub 2023. PMID: 37226898.
36. Abdelsalam ME, Awad A, Baiomy A, Irwin D, Karam JA, Matin SF, Sheth RA, Habibollahi P, Odisio BC, Lu T, Ahrar K. Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765867.
37. Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SM. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass 4(1):81-87, 2023. e-Pub 2023. PMID: 36569509.
38. Pollard AC, Paolillo V, Radaram B, Qureshy S, Li L, Maity T, Wang L, Uddin MN, Wood CG, Karam JA, Pagel MD, Piwnica-Worms D, Millward SW, Fowlkes NW, Norton W, Engel BJ, Pisaneschi F, Zacharias NM. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine. Mol Imaging Biol 24(6):959-972, 2022. e-Pub 2022. PMID: 35732988.
39. Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010). Lancet 400(10358):1103-1116, 2022. e-Pub 2022. PMID: 36099926.
40. Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK, Investigators K. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564). Lancet Oncol 23(9):1133-1144, 2022. e-Pub 2022. PMID: 36055304.
41. Pieretti AC, Ozambela M, Westerman ME, Nogueras-Gonzalez GM, Segarra LA, Zacharias NM, Vaporciyan A, Hofstetter W, Huynh T, Aldousari S, Matin SF, Karam JA. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer 20(4):e330-e338, 2022. e-Pub 2022. PMID: 35279419.
42. Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma. BJU Int 129(6):718-722, 2022. e-Pub 2022. PMID: 34480522.
43. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation. BJU Int 129(5):610-620, 2022. e-Pub 2022. PMID: 34228889.
44. Westerman ME, Yevich SM, Dori Y, Ward JF, Pisters LL, Karam JA, Wood CG, Avritscher R, Matin SF. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urologic surgery. BJU Int 129(5):585-587, 2022. e-Pub 2022. PMID: 34962705.
45. Falahkheirkhah K, Guo T, Hwang M, Tamboli P, Wood CG, Karam JA, Sircar K, Bhargava R. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Invest 102(5):554-559, 2022. e-Pub 2022. PMID: 34963688.
46. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
47. Srougi V, Bancos I, Daher M, Lee JE, Graham PH, Karam JA, Henriquez A, Mckenzie TJ, Sada A, Bourdeau I, Poirier J, Vaidya A, Abbondanza T, Kiernan CM, Rao SN, Hamidi O, Sachithanandan N, Hoff AO, Chambo JL, Almeida MQ, Habra MA, MCBV F. Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival. J Clin Endocrinol Metab 107(4):964-971, 2022. e-Pub 2022. PMID: 34850915.
48. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267435.
49. Collaborative C, Collaborative G. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia 77(1):28-39, 2022. e-Pub 2022. PMID: 34428858.
50. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39(12):837.e9-837.e17, 2021. e-Pub 2021. PMID: 34551888.
51. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
52. Shapiro, DD, Soeung, M, Perelli, L, Dondossola, E, Surasi, DS, Tripathi, DN, Bertocchio, JP, Carbone, F, Starbuck, MW, Van Alstine, ML, Rao, P, Katz, MH, Parker, NH, Shah, AY, Carugo, A, Heffernan, TP, Schadler, KL, Logothetis, CJ, Walker, CL, Wood, CG, Karam, JA, Draetta, G, Tannir, NM, Genovese, G, Msaouel, P. Association of high-intensity exercise with renal medullary carcinoma in individuals with sickle cell trait. Cancers 13(23), 2021. e-Pub 2021. PMID: 34885132.
53. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
54. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
55. Takahashi H, Vikram R, Jimenez RE, Bolan CW, Kawashima A, Karam JA, Takahashi N. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma. Abdom Radiol (NY) 46(11):5250-5259, 2021. e-Pub 2021. PMID: 34338814.
56. Collaborative C, Collaborative G. Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. Anaesthesia 76(11):1454-1464, 2021. e-Pub 2021. PMID: 34371522.
57. Collaborative C, Collaborative G. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. Br J Surg 108(9):1056-1063, 2021. e-Pub 2021. PMID: 33761533.
58. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T, Investigators K. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 385(8):683-694, 2021. e-Pub 2021. PMID: 34407342.
59. Abdelsalam ME, Sabir SH, Ba SBK, Karam JA, Matin SF, Wood CG, Ahrar K. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol 217(1):1-7, 2021. e-Pub 2021. PMID: 33909469.
60. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline Part I. J Urol:101097JU0000000000001911. e-Pub 2021. PMID: 34115547.
61. Campbell SC, Uzzo RG, Karam JA, Chang SS, Clark PE, Souter L. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol:101097JU0000000000001912. e-Pub 2021. PMID: 34115531.
62. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res 27(11):3265, 2021. e-Pub 2021. PMID: 34074655.
63. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
64. Zacharias NM, Wang L, Maity T, Li L, Millward SW, Karam JA, Wood CG, Navai N. Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. Int J Mol Sci 22(6), 2021. e-Pub 2021. PMID: 33799686.
65. GlobalSurg Collaborative CC. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia 76(6):748-758, 2021. e-Pub 2021. PMID: 33690889.
66. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
67. Sharma P, Goswami S, Gao J, Basu S, Shapiro D, Karam JA, Tidwell R, Ahrar K, Campbell M, Shen Y, Trevino A, Mayer A, Espejo A, Seua C, Macaluso M, Chen Y, Liu W, He Z, Yadav S, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Futreal A, Wang L, Tannir N. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma. Nature.

Invited Articles

1. McIntosh AG, Umbreit EC, Wood CG, Matin SF, Karam JA. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol 10(5):2233-2245, 2021. e-Pub 2021. PMID: 34159106.
2. Umbreit EC, McIntosh AG, Suk-Ouichai C, Karam JA, Wood CG. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian J Urol 37(1):13-19, 2021. e-Pub 2021. PMID: 33850351.

Review Articles

1. Shapiro DD, Abel EJ, Albiges L, Battle D, Berg SA, Campbell MT, Cella D, Coleman K, Garmezy B, Geynisman DM, Hall T, Henske EP, Jonasch E, Karam JA, La Rosa S, Leibovich BC, Maranchie JK, Master VA, Maughan BL, McGregor BA, Msaouel P, Pal SK, Perez J, Plimack ER, Psutka SP, Riaz IB, Rini BI, Shuch B, Simon MC, Singer EA, Smith A, Staehler M, Tang C, Tannir NM, Vaishampayan U, Voss MH, Zakharia Y, Zhang Q, Zhang T, Carlo MI. Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank. Urol Oncol, 2025. e-Pub 2025. PMID: 40820078.
2. Makrakis D, Msaouel P, Karam JA, Esagian SMu. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis of Individual Patient Data. Eur Urol Focus, 2024. e-Pub 2024. PMID: 39667984.
3. Esagian, SM, Karam, JA, Msaouel, P, Makrakis, D. Upfront (uCN) vs. deferred (dCN) cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 42:440, 2024. e-Pub 2024.
4. Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP. Epidemiology of Renal Cell Carcinoma. Eur Urol 82(5):529-542, 2022. e-Pub 2022. PMID: 36100483.
5. Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers (Basel) 14(16), 2022. e-Pub 2022. PMID: 36010916.

Other Articles

1. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2026. PMID: 41621415.
2. Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy. Eur Urol Oncol 6(6):638-639, 2023. PMID: 37268448.
3. Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 50:43-46, 2023. PMID: 36861106.
4. Master VA, Uzzo RG, Bratlavsky G, Karam JA Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer. Eur Urol Focus 8(3):651-653, 2022. PMID: 35662502.

Abstracts

1. Abdelsalam M, Mecci N, Matin S, Wood C, Karam J, Ahrar K. Abstract No. 587 Magnetic resonance imaging–guided cryoablation of de novo solitary pathologically proven T1a renal tumors. Journal of Vascular and Interventional Radiology 32(5):S165. e-Pub 2021.

Book Chapters

1. Ellis, EE, Cotta, BH, Karam, JA, Merril, MM. Postoperative Surveillance Protocols for Renal Cell Carcinoma, 391-418, 2025.

Letters to the Editor

1. Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. Eur Urol Oncol 7: 302-303, 2024.
2. Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re. Eur Urol 84: e55-e56, 2023.
3. Klatte T, Welsh SJ, Riddick ACP, Karam JA, Stewart GD. Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus. BJU Int 131: 566-568, 2023.